Trial Profile

A Phase II Study of Niraparib in Combination With EGFR Inhibitor Panitumumab in Patients With Advanced Colorectal Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 14 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Niraparib (Primary) ; Panitumumab (Primary)
Indications Colorectal cancer
Focus Therapeutic Use
Acronyms NIPAVect

Most Recent Events

09 Apr 2025 The protocol has been amended to change in study time frame.
09 Apr 2025 Planned End Date changed from 31 Oct 2024 to 31 Oct 2025.
06 Jun 2023 Results assessing safety and efficacy of the combination of niraparib and panitumumab in patients with advanced colorectal cancer, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com